FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2528163604> ?p ?o ?g. }

• W2528163604 endingPage "254" @default.
• W2528163604 startingPage "250" @default.
• W2528163604 abstract "We describe a Canadian phase III randomized controlled trial of stereotactic body radiotherapy (SBRT) versus conventionally hypofractionated radiotherapy (CRT) for the treatment of stage I medically inoperable non-small-cell lung cancer (OCOG-LUSTRE Trial). Eligible patients are randomized in a 2:1 fashion to either SBRT (48 Gy in 4 fractions for peripherally located lesions; 60 Gy in 8 fractions for centrally located lesions) or CRT (60 Gy in 15 fractions). The primary outcome of the study is 3-year local control, which we hypothesize will improve from 75% with CRT to 87.5% with SBRT. With 85% power to detect a difference of this magnitude (hazard ratio = 0.46), a 2-sided α = 0.05 and a 2:1 randomization, we require a sample size of 324 patients (216 SBRT, 108 CRT). Important secondary outcomes include overall survival, disease-free survival, toxicity, radiation-related treatment death, quality of life, and cost-effectiveness. A robust radiation therapy quality assurance program has been established to assure consistent and high quality SBRT and CRT delivery. Despite widespread interest and adoption of SBRT, there still remains a concern regarding long-term control and risks of toxicity (particularly in patients with centrally located lesions). The OCOG-LUSTRE study is the only randomized phase III trial testing SBRT in a medically inoperable population, and the results of this trial will attempt to prove that the benefits of SBRT outweigh the potential risks." @default.
• W2528163604 created "2016-10-14" @default.
• W2528163604 creator A5002290683 @default.
• W2528163604 creator A5002547008 @default.
• W2528163604 creator A5006264564 @default.
• W2528163604 creator A5007941548 @default.
• W2528163604 creator A5009277937 @default.
• W2528163604 creator A5016064316 @default.
• W2528163604 creator A5023649795 @default.
• W2528163604 creator A5026555468 @default.
• W2528163604 creator A5027918729 @default.
• W2528163604 creator A5038486476 @default.
• W2528163604 creator A5044903935 @default.
• W2528163604 creator A5050860970 @default.
• W2528163604 creator A5051305867 @default.
• W2528163604 creator A5057219088 @default.
• W2528163604 creator A5063012663 @default.
• W2528163604 creator A5064693052 @default.
• W2528163604 creator A5070388904 @default.
• W2528163604 creator A5070655789 @default.
• W2528163604 creator A5072729397 @default.
• W2528163604 creator A5072962607 @default.
• W2528163604 creator A5081336329 @default.
• W2528163604 creator A5087037519 @default.
• W2528163604 date "2017-03-01" @default.
• W2528163604 modified "2023-10-16" @default.
• W2528163604 title "Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial" @default.
• W2528163604 cites W1972491414 @default.
• W2528163604 cites W1990266033 @default.
• W2528163604 cites W2000325856 @default.
• W2528163604 cites W2005842510 @default.
• W2528163604 cites W2020870950 @default.
• W2528163604 cites W2024107960 @default.
• W2528163604 cites W2050158980 @default.
• W2528163604 cites W2051021899 @default.
• W2528163604 cites W2057604474 @default.
• W2528163604 cites W2115646671 @default.
• W2528163604 cites W2115718867 @default.
• W2528163604 cites W2121902152 @default.
• W2528163604 cites W2138642779 @default.
• W2528163604 cites W2151020778 @default.
• W2528163604 cites W2159746573 @default.
• W2528163604 cites W2179010101 @default.
• W2528163604 cites W2309884927 @default.
• W2528163604 cites W2326531429 @default.
• W2528163604 cites W2333478622 @default.
• W2528163604 doi "https://doi.org/10.1016/j.cllc.2016.08.002" @default.
• W2528163604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27876603" @default.
• W2528163604 hasPublicationYear "2017" @default.
• W2528163604 type Work @default.
• W2528163604 sameAs 2528163604 @default.
• W2528163604 citedByCount "28" @default.
• W2528163604 countsByYear W25281636042018 @default.
• W2528163604 countsByYear W25281636042019 @default.
• W2528163604 countsByYear W25281636042020 @default.
• W2528163604 countsByYear W25281636042021 @default.
• W2528163604 countsByYear W25281636042022 @default.
• W2528163604 countsByYear W25281636042023 @default.
• W2528163604 crossrefType "journal-article" @default.
• W2528163604 hasAuthorship W2528163604A5002290683 @default.
• W2528163604 hasAuthorship W2528163604A5002547008 @default.
• W2528163604 hasAuthorship W2528163604A5006264564 @default.
• W2528163604 hasAuthorship W2528163604A5007941548 @default.
• W2528163604 hasAuthorship W2528163604A5009277937 @default.
• W2528163604 hasAuthorship W2528163604A5016064316 @default.
• W2528163604 hasAuthorship W2528163604A5023649795 @default.
• W2528163604 hasAuthorship W2528163604A5026555468 @default.
• W2528163604 hasAuthorship W2528163604A5027918729 @default.
• W2528163604 hasAuthorship W2528163604A5038486476 @default.
• W2528163604 hasAuthorship W2528163604A5044903935 @default.
• W2528163604 hasAuthorship W2528163604A5050860970 @default.
• W2528163604 hasAuthorship W2528163604A5051305867 @default.
• W2528163604 hasAuthorship W2528163604A5057219088 @default.
• W2528163604 hasAuthorship W2528163604A5063012663 @default.
• W2528163604 hasAuthorship W2528163604A5064693052 @default.
• W2528163604 hasAuthorship W2528163604A5070388904 @default.
• W2528163604 hasAuthorship W2528163604A5070655789 @default.
• W2528163604 hasAuthorship W2528163604A5072729397 @default.
• W2528163604 hasAuthorship W2528163604A5072962607 @default.
• W2528163604 hasAuthorship W2528163604A5081336329 @default.
• W2528163604 hasAuthorship W2528163604A5087037519 @default.
• W2528163604 hasConcept C126322002 @default.
• W2528163604 hasConcept C126838900 @default.
• W2528163604 hasConcept C143998085 @default.
• W2528163604 hasConcept C155806632 @default.
• W2528163604 hasConcept C168563851 @default.
• W2528163604 hasConcept C204243189 @default.
• W2528163604 hasConcept C207103383 @default.
• W2528163604 hasConcept C2776256026 @default.
• W2528163604 hasConcept C2780387249 @default.
• W2528163604 hasConcept C2908647359 @default.
• W2528163604 hasConcept C44249647 @default.
• W2528163604 hasConcept C509974204 @default.
• W2528163604 hasConcept C535046627 @default.
• W2528163604 hasConcept C71924100 @default.
• W2528163604 hasConcept C99454951 @default.
• W2528163604 hasConceptScore W2528163604C126322002 @default.
• W2528163604 hasConceptScore W2528163604C126838900 @default.

• next